Winona Prescription Process: How the HRT Telehealth Intake Works

How the Winona Intake Process Works

Winona uses a questionnaire-based intake that takes roughly 10 to 15 minutes. You answer questions about menopause symptoms, medical history, current medications, family history of breast cancer and blood clots, and treatment preferences. A licensed physician reviews the submission asynchronously and either approves a prescription, requests more information, or declines treatment.

The model mirrors what the American Telemedicine Association has described as "store-and-forward" care, where clinical data is collected and reviewed without a real-time encounter [1]. This is a common format in dermatology and sexual health telehealth, now extended to menopause. Winona states that its physicians are licensed in the patient's state, which is a standard regulatory requirement under state medical board rules.

One thing the intake does not include by default: lab work. The Endocrine Society's 2015 clinical practice guideline on menopausal HRT recommends a baseline assessment including lipid panel, mammography status, and evaluation of cardiovascular risk factors before initiating estrogen therapy [2]. The North American Menopause Society (NAMS) 2022 position statement similarly advises individualized risk assessment that accounts for age, time since menopause, and personal thrombotic history [3]. Winona's questionnaire captures some of this through self-reported data. But self-report is not a lipid panel.

Whether this matters depends on the patient's risk profile. For a healthy 52-year-old woman within 10 years of her last period, the absolute cardiovascular risk of transdermal estradiol is low. The Women's Health Initiative (WHI) reanalysis by Manson et al. found that women aged 50 to 59 who initiated conjugated equine estrogens had a hazard ratio for coronary heart disease of 0.93 (95% CI: 0.65 to 1.33), showing no increased risk [4]. For a 63-year-old with undiagnosed hypertension, skipping baseline labs carries a different calculus entirely.

What Medications Does Winona Prescribe?

Winona's formulary centers on bioidentical hormones dispensed through a compounding pharmacy. The primary offerings are estradiol (topical cream or oral), micronized progesterone, combination estradiol-progesterone creams, and DHEA.

These are not fringe compounds. Estradiol is the most potent endogenous estrogen and the form recommended as first-line by NAMS [3]. Micronized progesterone (the same active ingredient as brand-name Prometrium) is the progestogen associated with the most favorable safety profile. A French prospective cohort study (E3N, N=80,377) published in Breast Cancer Research and Treatment found that estradiol combined with micronized progesterone carried no statistically significant increase in breast cancer risk over a mean follow-up of 8.1 years, compared to a relative risk of 1.69 for synthetic progestins [5].

The distinction that matters here is compounded versus FDA-approved. Winona's medications come from a compounding pharmacy, not as commercially manufactured products. The FDA has stated that compounded drugs "are not FDA-approved" and "do not undergo FDA premarket review for safety, effectiveness, or quality" [6]. The active ingredients may be identical to those in FDA-approved products, but the final formulation lacks the batch-to-batch consistency testing that manufactured drugs receive.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the WHI, has noted: "Compounded bioidentical hormones are often marketed as safer or more natural, but they have the same risks as their FDA-approved counterparts and lack the quality controls" [7]. This is not a reason to avoid Winona categorically. It is a reason to understand what you are getting.

Is Winona a Legitimate Medical Service?

Yes, in the regulatory sense. Winona operates as a telehealth platform using licensed physicians who prescribe within their state licensure. The company partners with licensed compounding pharmacies. This structure is legal in all 50 states under current telehealth practice laws, though specific prescribing rules vary by state.

Legitimate does not mean optimal for every patient. The 2022 NAMS position statement emphasizes that "the decision to use HT should be individualized based on a woman's symptoms, age, time since menopause, and individual risk profile for cardiovascular disease, venous thromboembolism, and breast cancer" [3]. A 10-minute online questionnaire reviewed asynchronously may capture enough data for low-risk patients. For women with complex medical histories, it may not.

The platform does have physician oversight. That separates it from supplement companies or wellness brands selling over-the-counter "hormone support" products with no prescriber involvement. Winona's physicians can decline to prescribe, adjust doses, and follow up through the messaging system.

A 2023 cross-sectional analysis published in JAMA Network Open found that among 1.2 million telehealth visits for hormone therapy, prescribing patterns were broadly consistent with guideline-recommended formulations, though the study noted that follow-up visit rates were lower than in traditional care settings [8]. That gap in follow-up is worth watching. Starting HRT is straightforward. Monitoring for endometrial safety, blood pressure changes, and symptom response over time requires ongoing attention.

How Much Does Winona Cost?

Winona operates on a cash-pay model with no insurance billing. Monthly costs range from approximately $89 for a single topical estradiol cream to $199 or more for combination regimens. The consultation fee is bundled into the medication cost; there is no separate office visit charge.

For comparison, FDA-approved estradiol patches (such as Climara or Vivelle-Dot) cost $30 to $75 per month with a GoodRx coupon at a retail pharmacy [9]. Generic oral micronized progesterone runs $15 to $40 per month. A patient with insurance who sees an in-network provider and fills FDA-approved prescriptions at a retail pharmacy could pay significantly less than Winona's cash price.

The value proposition is convenience and speed. No appointment scheduling, no waiting room, no insurance prior authorization. For women whose primary barrier to HRT access is time or geographic distance from a menopause specialist, that convenience has real clinical value. A 2021 survey published in Menopause found that 73% of ob-gyn residency programs provided no formal menopause education, leaving many women unable to find a knowledgeable local provider [10]. Telehealth fills that gap, if imperfectly.

Winona vs. Alternatives: How the Platform Compares

Several telehealth platforms now offer HRT for menopause. The most direct competitors include Midi Health, Evernow, and Alloy. Each differs in clinical model, formulary, and cost.

Midi Health uses synchronous video visits with menopause-trained clinicians and prescribes FDA-approved medications through retail pharmacies. This is closer to a traditional medical model delivered remotely. Evernow uses a similar asynchronous questionnaire to Winona but also primarily prescribes FDA-approved formulations. Alloy offers both FDA-approved and compounded options with an online intake.

The core tradeoff across all these platforms is the same: convenience versus depth of evaluation. A board-certified menopause specialist who orders labs, reviews imaging, and spends 30 minutes with a patient will deliver a more thorough risk assessment than any asynchronous intake form. The problem is access. Only about 1,000 physicians in the United States hold NAMS certification in menopause medicine [11]. That number cannot serve the estimated 1.3 million women who enter menopause each year in the U.S. [12].

Winona's specific differentiator is its focus on compounded bioidentical formulations. If a patient specifically wants a compounded cream rather than a manufactured patch or pill, Winona's formulary is designed for that preference. If a patient is indifferent to compounded versus FDA-approved and wants the lowest cost, a platform that prescribes generics filled at a retail pharmacy may be more economical.

Clinical Evidence: Does Telehealth HRT Work?

The question is not whether telehealth works in general but whether the specific telehealth model Winona uses provides adequate clinical oversight for hormone therapy.

The medications themselves have strong evidence. The WHI and its subsequent reanalyses, along with dozens of randomized trials, establish that estrogen therapy reliably reduces hot flash frequency by 75% or more [4]. The REPLENISH trial (N=1,835) demonstrated that a combination of estradiol and progesterone in a single oral capsule reduced moderate-to-severe hot flashes by 81% compared to 54% with placebo at 12 weeks [13]. These benefits apply regardless of whether the prescription comes from a telehealth platform or a brick-and-mortar clinic.

Where the evidence thins is on long-term safety monitoring delivered through asynchronous telehealth. For women with a uterus taking estrogen, adequate progestogen coverage is necessary to prevent endometrial hyperplasia. The Endocrine Society recommends endometrial monitoring in women on estrogen therapy, particularly if bleeding occurs [2]. Whether a messaging-based follow-up system catches these signals as reliably as periodic in-person visits is an open question.

A practical approach: use a platform like Winona for access and convenience, but maintain a relationship with a primary care provider or gynecologist who can order periodic labs and imaging. This is not an either-or decision.

What Reviews Actually Say About Winona

Winona reviews across consumer platforms tend to cluster around two themes. Satisfied users praise the speed, the elimination of appointment barriers, and symptom relief. Dissatisfied users cite cost relative to generic alternatives, customer service responsiveness, and auto-ship billing confusion.

These patterns are not unique to Winona. They are consistent across nearly every subscription telehealth pharmacy model. The clinical signal in the reviews is that the medications work, which is expected given that the active compounds are well-studied. The negative signal is about the business model: recurring charges, cancellation friction, and the premium over retail pharmacy pricing.

No telehealth platform should be evaluated primarily through consumer reviews. The better question is whether the clinical model meets guideline standards. For low-risk women within 10 years of menopause onset seeking standard-dose transdermal estradiol and micronized progesterone, Winona's prescribing model aligns with NAMS recommendations [3]. For higher-risk patients or those requiring dose titration based on lab values, the model has gaps that the patient must fill through other care relationships.

Who Should Consider Winona and Who Should Not

Winona is a reasonable option for women who meet specific criteria: age 40 to 60, within 10 years of menopause onset, no personal history of breast cancer or venous thromboembolism, no uncontrolled hypertension, and primary symptoms of vasomotor instability (hot flashes, night sweats) or genitourinary syndrome of menopause.

Women who should seek in-person evaluation before starting HRT include those with a personal history of breast cancer, prior VTE, active liver disease, unexplained vaginal bleeding, or coronary artery disease. The USPSTF recommends against using hormone therapy for the prevention of chronic conditions in postmenopausal women, giving it a D recommendation for that specific indication [14]. That recommendation does not apply to symptomatic treatment, but it underscores that HRT is not risk-free and requires individualized assessment.

The most practical screening question a woman can ask herself before choosing any telehealth HRT platform: "Would a doctor who had my full medical record and labs in front of them prescribe this?" If the answer is confidently yes, the convenience of telehealth is a net positive. If there is any uncertainty, an in-person visit with lab work is worth the extra effort.

Transdermal estradiol at standard doses (0.025 to 0.05 mg/day patch equivalent) carries a lower VTE risk than oral estrogen, with the ESTHER study finding no significant VTE increase for transdermal routes (OR 0.9, 95% CI: 0.5 to 1.6) compared to an OR of 4.2 for oral estrogen [15].